



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Ruben et al.

Docket No. PF155C1P1D1

Application No.: 10/733,311

Confirmation No.: 8060

Filed: December 12, 2003

Art Unit: 1647

For: Keratinocyte Growth Factor-2

Examiner: C.J. Saoud

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-GG listed on the attached Form PTO/SB/08. Legible copies of references CF-CJ, CL-CS, CU-CW, CZ-DB, DG, DI-DN, DP, DR-DS, DW-EA, and ED-EG are provided herewith.

Copies of references AA-CE, CK, CT, CX-CY, DC-DF, DH, DO, DQ, DT-DV, EB-EC, and EH-GG were submitted by Applicants or cited by the Examiner in connection with U. S. Patent Application Serial No. 09/345,373 (now U.S. Patent No. 6,903,072), filed July 1, 1999, and U. S. Patent Application Serial No. 09/610,651 (now U.S. Patent No. 6,693,077), filed June 30, 2000 to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the above-listed files for copies of reference(s) AA-CE, CK, CT, CX-CY, DC-DF, DH, DO, DQ, DT-DV, EB-EC, and EH-GG.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR § 1.104(a) concerning

the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed reference(s) is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Please charge any fees due, or credit any overpayment, to our Deposit Account No. 08-3425.

Dated: May 5, 2006

Respectfully submitted,

By   
Karen L. Carroll

Registration No.: 50,748  
HUMAN GENOME SCIENCES, INC.  
Intellectual Property Dept.  
14200 Shady Grove Road  
Rockville, Maryland 20850  
(301) 315-1768

MJH/KC/pb



PTO/SB/08a/b (06-03)  
Approved for use through 07/31/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
				Application Number	10/733,311-Conf#8060
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Filing Date	December 12, 2003
				First Named Inventor	Ruben et al.
				Art Unit	1647
				Examiner Name	C. Saoud
Sheet	1	of	9	Attorney Docket Number	PF155C1P1D1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	5,194,596	03/16/1993	Tischer <i>et al.</i>	
	AB	5,350,836	09/27/1994	Kopchick <i>et al.</i>	
	AC	5,580,856	12/03/1996	Prestrelski <i>et al.</i>	
	AD	5,677,278	10/14/1997	Gospodarowicz <i>et al.</i>	
	AE	5,703,047	12/30/1997	Wilson, S.E.	
	AF	5,731,170	03/24/1998	Rubin <i>et al.</i>	
	AG	5,773,252	06/30/1998	Greene <i>et al.</i>	
	AH	5,773,586	06/30/1998	Gospodarowicz <i>et al.</i>	
	AI	5,814,605	09/29/1998	Pierce <i>et al.</i>	
	AJ	5,824,643	10/20/1998	Pierce <i>et al.</i>	
	AK	5,843,883	12/01/1998	Gospodarowicz <i>et al.</i>	
	AL	5,863,767	01/26/1999	Gospodarowicz <i>et al.</i>	
	AM	6,077,692	06/20/2000	Ruben <i>et al.</i>	
	AN	6,238,888 B1	05/29/2001	Gentz <i>et al.</i>	
	AO	6,599,879	07/29/2003	Jimmenez <i>et al.</i>	
	AP	6,653,284	05/14/2001	Gentz <i>et al.</i>	
	AQ	6,693,077	02/17/2004	Ruben <i>et al.</i>	
	AQ	6,869,927	03/22/2005	Gentz <i>et al.</i>	
	AR	6,903,072	06/07/2005	Ruben <i>et al.</i>	
	AS	6,916,786	07/12/2005	Ruben <i>et al.</i>	
	AT	2002/0016295 A1	02/07/2002	Gentz <i>et al.</i>	
	AU	2003/0077695 A1	04/24/2003	Ruben <i>et al.</i>	
	AV	2003/0119108 A1	06/26/2003	Laird <i>et al.</i>	
	AW	2003/0129687 A1	07/10/2003	Ruben <i>et al.</i>	
	AX	2003/0186904 A1	10/02/2003	Ruben <i>et al.</i>	
	AY	09/912,292	NOT PUBLISHED	Rosen <i>et al.</i>	Pages 1-75 (Pages 1 & 2 partially redacted); portion of Table 2; and SEQ ID NO:40589

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	AZ	WO 90/08771	08/09/1990	Rubin <i>et al.</i>		
	BA	WO 92/14480	09/03/1992	Amgen Inc.		
	BB	WO 92/22304	12/23/1992	Amgen Inc.		
	BC	WO 93/21908	11/11/1993	Amgen Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/733,311-Conf#8060
				Filing Date	December 12, 2003
				First Named Inventor	Ruben et al.
				Art Unit	1647
				Examiner Name	C. Saoud
Sheet	2	of	9	Attorney Docket Number	PF155C1P1D1

	BD	EP 0 619 370 A1	10/12/1994	Amgen Inc.		
	BE	WO 94/22427	10/13/1994	Amgen Inc.		
	BF	WO 94/23032	10/13/1994	Amgen Inc.		
	BG	WO 95/01434	01/12/1995	Chiron Inc.		
	BH	WO 95/03831	02/09/1995	Prizm Pharmaceuticals, Inc.		
	BI	WO 95/24928	09/21/1995	Prizm Pharmaceuticals, Inc.		
	BJ	WO 95/24928 A3	09/21/1995	Prizm Pharmaceuticals, Inc.		
	BK	JP 7-345689	12/07/1995	Sumitomo Pharmaceuticals Co., Ltd.		
	BL	JP 8-103240	03/28/1996	Sumitomo Pharmaceuticals Co., Ltd.		
	BM	WO 96/11949	04/25/1996	Amgen Inc.		
	BN	WO 96/11950	04/25/1996	Amgen Inc.		
	BO	WO 96/11951	04/25/1996	Amgen Inc.		
	BP	WO 96/11952	04/25/1996	Amgen Inc.		
	BQ	JP 8-214378	07/24/1996	Sumitomo Pharmaceuticals Co., Ltd.		
	BR	WO 96/22369	07/25/1996	Amgen Inc.		
	BS	WO 96/25422	08/22/1996	Human Genome Sciences, Inc.		
	BT	WO 97/20929	12/06/1997	Sumitomo Pharmaceuticals Co., Ltd.		
	BU	WO 98/06844	02/19/1998	Human Genome Sciences, Inc.		
	BV	WO 98/16243	04/23/1998	Amgen, Inc.		
	BW	WO 98/16642	04/23/1998	Amgen, Inc.		
	BX	GB 2 321 852 A	08/12/1998	Rohto Pharmaceutical Co. Ltd.		
	BY	JP 10-330283	12/15/1998	Sumitomo Seiyaku Corp. Ltd.		
	BZ	JP 10-330284	12/15/1998	Sumitomo Seiyaku Corp. Ltd.		
	CA	JP 10-330285	12/15/1998	Sumitomo Seiyaku Corp. Ltd.		
	CB	WO 99/32135	07/01/1999	Human Genome Sciences, Inc.		
	CC	WO 99/41282	08/19/1999	Human Genome Sciences, Inc.		
	CD	WO 00/72872	12/07/2000	Human Genome Sciences, Inc.		
	CE	WO 01/02433	01/11/2001	Human Genome Sciences, Inc.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
				Application Number	10/733,311-Conf#8060
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Filing Date	December 12, 2003
				First Named Inventor	Ruben et al.
				Art Unit	1647
				Examiner Name	C. Saoud
				Attorney Docket Number	PF155C1P1D1
Sheet	3	of	9		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CF	ABRAHAM, <i>et al.</i> , "Phenotypic Control of Gap Junctional Communication by Cultured Alveolar Epithelial Cells," <i>American Physiological Society</i> , L825-L834 (1999).	
	CG	ALDERSON, <i>et al.</i> , "In Vitro and in Vivo Effects of Repifermin (Keratinocyte Growth Factor-2, KGF-2) on Human Carcinoma Cells," <i>Cancer Chemother Pharmacol</i> 50: 202-212 (2002).	
	CH	BANEYX, F., <i>et al.</i> , "In Vivo Degradation of Secreted Fusion Proteins by the <i>Escherichia coli</i> Outer Membrane Protease OmpT." <i>J. Bacteriology</i> 172(I):491-494 (1990).	
	CI	BASS, S., <i>et al.</i> , "Multicopy Suppressors of Prc Mutant <i>Escherichia coli</i> Include Two HtrA (DegP) Protease Homologs (HhoAB), DksA, and a Truncated RlpA," <i>J. Bacteriol.</i> 178:1154-1161, American Society for Microbiology (1996).	
	CJ	BOOTH, <i>et al.</i> , "Protection Against Mucosal Injury by Growth Factors and Cytokines," <i>Journal of the National Cancer Institute Monographs</i> , No. 29 (2001).	
	CK	BOWIE, J.U., <i>et al.</i> , "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," <i>Science</i> 247:1306-1310, American Association for the Advancement of Science (1990).	
	CL	CHEN <i>et al.</i> , "Stabilization of recombinant human keratinocyte growth factor by osmolytes and salts", <i>J. Pharm. Sciences</i> 85(4):419-422 (1996).	
	CM	CHEN <i>et al.</i> , "Aggregation pathway of recombinant human keratinocyte growth factor and its stabilization", <i>Pharmaceutical Research</i> 11(11):1581-1587 (1994).	
	CN	CLARKSON, <i>et al.</i> , "Interventions for Preventing Oral Mucositis for Patients with Cancer Receiving Treatment (Review)," <i>The Cochrane Collaboration</i> (2005).	
	CO	CUI, <i>et al.</i> , "The Effect of Keratinocyte Growth Factor-2 on Esophagogastric Anastomotic Wound Healing in Rats," <i>Journal of Surgical Investigation</i> , Vol. 1, No. 4, 307-309 (1999).	
	CP	DANILENKO, D., "Preclinical and Early Clinical Development of Keratinocyte Growth Factor, an Epithelial-Specific Tissue Growth Factor," <i>Toxicologic Pathology</i> , Vol. 27, No. 1, 64-71 (1999).	
	CQ	DODD, <i>et al.</i> , "Factors Influencing Oral Mucositis in Patients Receiving Chemotherapy," <i>Cancer Practice</i> , November/December, Vol. 8, No. 6 (2000).	
	CR	DÖRR, <i>et al.</i> , "Modification of Oral Mucositis by Keratinocyte Growth Factor: Single Radiation Exposure," <i>Int. J. Radiat. Biol.</i> , Vol. 77, No. 3, 341-347 (2001).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/733,311-Conf#8060
				Filing Date	December 12, 2003
				First Named Inventor	Ruben et al.
				Art Unit	1647
				Examiner Name	C. Saoud
Sheet	4	of	9	Attorney Docket Number	PF155C1P1D1

CS	FARRELL, <i>et al.</i> , "Keratinocyte Growth Factor Protects Mice from Chemotherapy and Radiation-induced Gastrointestinal Injury and Mortality," <i>Cancer Research</i> 58, 933-939, March (1998).
CT	FINCH, P.W., <i>et al.</i> , "Human KGF Is FGF-Related with Properties of a Paracrine Effector of Epithelial Cell Growth," <i>Science</i> 245:752-755, American Association for the Advancement of Science (1989).
CU	GREENWOOD-VAN MEERVELD, <i>et al.</i> , "Efficacy of Repifermin (Keratinocyte Growth Factor-2) Against Abnormalities in Gastrointestinal Mucosal Transport in a Murine Model of Colitis," <i>Journal of Pharmacy and Pharmacology</i> , 55: 67-75 (2003).
CV	HAN <i>et al.</i> , "Keratinocyte Growth Factor-2 (FGF-10) Promotes Healing of Experimental Small Intestinal Ulceration in Rats," <i>Am J of Physiol Gastrointest Liver Physiol</i> , 279(5, Pt. 1), G1011-G1022 (2000).
CW	HAN, <i>et al.</i> , Database Caplus, DN 134:13722; <i>American Journal of Physiology</i> (2000) 279(5, Pt.1), G1011-G1022.
CX	HARTUNG, H., <i>et al.</i> , "Murine FGF-12 and FGF-13: expression in embryonic nervous system, connective tissue and heart," <i>Mech. Dev.</i> 64:31-39, Elsevier Science Ireland Ltd. (1997).
CY	HARTUNG, H., <i>et al.</i> , "Assignment <sup>a</sup> of <i>Fgf12</i> to mouse chromosome bands 16B1→B3 in situ hybridization," <i>Cytogenet. Cell Genet.</i> 76:185-186, Karger A.G. (1997).
CZ	HASELTINE, W., "Genomics and Drug Discovery," <i>J Am Acad Dermatol</i> , 473-475, September (2001).
DA	IGARASHI, . <i>et al.</i> , "Characterization of Recombinant Human Fibroblast Growth Factor (FGF) - 10 Reveals Functional Similarities with Keratinocyte Growth Factor (FGF-7)," <i>J. Biological Chemistry</i> 273(21):13230-13235 (1998).
DB	INNES, D., <i>et al.</i> , "The cryptic <i>ushA</i> gene ( <i>ushA<sup>c</sup></i> ) in natural isolates of <i>Salmonella enterica</i> (serotype Typhimurium) has been inactivated by a single missense mutation," <i>Microbiology</i> 147: 1887-1896, Society for General Microbiology (July 2001).
DC	JIMENEZ, P., <i>et al.</i> , "Effect of Topical Keratinocyte Growth Factor-2 on Wound Healing In A Glucocorticoid-Impaired Model," <i>J. Cutan. Pathol.</i> 24:105, Munksgaard (1997).
DD	JIMENEZ, P.A., <i>et al.</i> , "Effect of Keratinocyte Growth Factor-2 on Cell Proliferation <i>In Vivo</i> ," <i>FASEB J.</i> 11:AS23, Abstract No. 3025, Federation of American Societies for Experimental Biology (1997).
DE	JIMENEZ, <i>et al.</i> , "Keratinocyte Growth Factor-2 Accelerates Wound Healing in Incisional Wounds," <i>J. Surg. Res.</i> 81:238-242, Academic Press, Inc. (1999).
DF	KELLEY, M.J., <i>et al.</i> , "Emergence of the keratinocyte growth factor multigene family during the great ape radiation," <i>Proc. Natl. Acad. Sci. USA</i> 89:9287-9291, National Academy of Sciences (1992).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/733,311-Conf#8060
				Filing Date	December 12, 2003
				First Named Inventor	Ruben et al.
				Art Unit	1647
				Examiner Name	C. Saoud
Sheet	5	of	9	Attorney Docket Number	PF155C1P1D1

	DG	JIMINEZ, <i>et al.</i> , Database Caplus, DN 133:12799; <i>New Cytokines as Potential Drugs</i> (2000), 101-119. Editors: Narula, et al.: Birkhaeuser Veriag. Basel, Switzerland.	
	DH	MASON, I.J., <i>et al.</i> , "FGF-7 (keratinocyte growth factor) expression during mouse development suggests roles in myogenesis, forebrain regionalisation and epithelial-mesenchymal interactions," <i>Mech. Dev.</i> 45:15-30, Elsevier Science Ireland Ltd. (1994).	
	DI	MATSUIKE, <i>et al.</i> , "Expression of Fibroblast Growth Factor (FGF)-10 in Human Colorectal Adenocarcinoma Cells," <i>J Nippon Med Sch</i> ; 68(5) (2001).	
	DJ	MATTHEWS, <i>et al.</i> , "Prevention of Mucositis in Irradiated Head and Neck Cancer Patients," <i>Journal of Experimental Therapeutics &amp; Oncology</i> , 1: 135-138 (1996).	
	DK	MCGEE, <i>et al.</i> , "Keratinocyte Growth Factor Promotes the Survival, Growth, and Differentiation of Preantral Ovarian Follicles," <i>Fertility and Sterility</i> , Vol. 71, No. 4, April (1999).	
	DL	MEERMAN, H.J., <i>et al.</i> , "Construction and Characterization of a Set of E. coli Strains Deficient in All Known Loci Affecting the Proteolytic Stability of Secreted Recombinant Proteins," <i>Bio/Technology</i> 12: 1107-1110 (1994).	
	DM	MICELI, <i>et al.</i> , "Efficacy of Keratinocyte Growth Factor-2 in Dextran Sulfate Sodium-Induced Murine Colitis," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 290(1):464-471 (1999).	
	DN	MICELI, <i>et al.</i> , Database Caplus, DN 131:282007; <i>Journal of Pharmacology and experimental Therapeutics</i> (1999), 290(1), 464-471.	
	DO	MIYAMOTO, M., <i>et al.</i> , "Molecular Cloning of a Novel Cytokine cDNA Encoding the Ninth Member of the Fibroblast Growth Factor Family, Which has a Unique Secretion Property," <i>Mol. Cell. Biol.</i> 13(7):4251-4259 (1993).	
	DP	MOSE, <i>et al.</i> , "Can Prophylactic Application of Immunoglobulin Decrease Radiotherapy-Induced Oral Mucositis?," <i>Am J Clin Oncol (CCT)</i> 20(4): 407-411 (1997).	
	DQ	NGO, J.T., <i>et al.</i> , "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," in: <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz, Jr., K. and Le Grand, S., eds., Birkhauser, Boston, Massachusetts, pp. 491-495 (1994).	
	DR	PIERCE, <i>et al.</i> , "Stimulation of all epithelial elements during skin regeneration by keratinocyte growth factor," <i>J. Exp. Med.</i> 179:831-8406 (1994).	
	DS	ROBSON, <i>et al.</i> , "Randomized Trial of Topically Applied Repifermin (Recombinant Human Keratinocyte Growth Factor-2) to Accelerate Wound Healing in Venous Ulcers," <i>Wound Repair and Regeneration</i> ; 9:347-352 (2001).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/733,311-Conf#8060
				Filing Date	December 12, 2003
				First Named Inventor	Ruben et al.
				Art Unit	1647
				Examiner Name	C. Saoud
Sheet	6	of	9	Attorney Docket Number	PF155C1P1D1

DT	ROBSON, <i>et al.</i> , "Modern ideas and notations relating to primary structure," in: <i>Introduction to Proteins and Protein Engineering</i> , Robson, B. and Garnier, J., eds., Elsevier Science, Amsterdam, The Netherlands, p.41 (1986).
DU	RON, D., <i>et al.</i> , "Expression of Biologically Active Recombinant Keratinocyte Growth Factor," <i>J. Biol. Chem.</i> 268(4):2984-2988, American Society for Biochemistry and Molecular Biology, Inc. (1993).
DV	WELLS, J.A., "Additivity of Mutational Effects in Proteins," <i>Biochem.</i> 29:8509-8517, American Chemical Society, (1990).
DW	SANAIE, <i>et al.</i> , "Keratinocyte Growth Factor (KGF)-1 and -2 Protein and Gene Expression in Human Gingival Fibroblasts," <i>J Periodont Res</i> , 37: 66-74 (2002).
DX	SCOPES, R.K. "Protein Purification: Principles and Practice" (3 <sup>rd</sup> ed.) New York: Springer-Verlag (1994).
DY	SMITH, <i>et al.</i> , "Efficacy of Growth Factors in the Accelerated Closure of Interstices in Explanted Meshed Human Skin Grafts," <i>Journal of Burn Care &amp; Rehabilitation</i> , January/February, 5-9 (2000).
DZ	STIFF, P., "Mucositis Associated with Stem Cell Transplantation: Current Status and Innovative Approaches to Management," <i>Bone Marrow Transplantation</i> , 27, Suppl. 2 (2001).
EA	SUNG, <i>et al.</i> , "Pharmacologic and Pharmacokinetic Profile of Repifermin (KGF-2) in Monkeys and Comparative Pharmacokinetics in Humans," <i>AAPS PharmSci</i> , 4 (2) article 8 (2002).
EB	YAMASAKI, M., <i>et al.</i> , "Structure and Expression of the Rat mRNA Encoding a Novel Member of the Fibroblast Growth Factor Family," <i>J. Biol. Chem.</i> 271:15918-15921, American Society for Biochemistry and Molecular Biology, Inc. (1996).
EC	YAN, G., <i>et al.</i> , "Sequence of Rat Keratinocyte Growth Factor (Heparin-Binding Growth Factor Type 7)," <i>In Vitro Cell. Dev. Biol.</i> 27A:437-438, Tissue Culture Association (1991).
ED	WANG, <i>et al.</i> , "Keratinocyte Growth Factor Induced Epithelial Proliferation Facilitates Retroviral-mediated Gene Transfer to Distal Lung Epithelia in vivo," <i>The Journal of Gene Medicine</i> , 1: 22-30 (1999).
EE	WHEELER, G., "Repifermin," <i>IDrugs</i> 4(7): 813-819 (2001).
EF	XIA, <i>et al.</i> , "Effects of Keratinocyte Growth Factor-2 (KGF-2) on Wound Healing in an Ischaemia-Impaired Rabbit Ear Model and on Scar Formation," <i>J. Pathol.</i> 188: 431-438 (1999).
EG	YANG, <i>et al.</i> , "Effect of Keratinocyte Growth Factor-2 on Proliferation of Human Adult Keratinocytes," <i>Chinese Journal of Traumatology (English Edition)</i> , 5(6): 342-345 (2002).
EH	NCBI Entrez, GenBank Report with Revision History, Accession No. T52063, Hillier, L. <i>et al.</i> , National Center for Biotechnology Information (February 1995).
EI	NCBI Entrez, GenBank Report with Revision History, Accession No. D46201, Sasaki, T. <i>et al.</i> , National Center for Biotechnology Information (August 1995).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/733,311-Conf#8060
				Filing Date	December 12, 2003
				First Named Inventor	Ruben et al.
				Art Unit	1647
				Examiner Name	C. Saoud
Sheet	7	of	9	Attorney Docket Number	PF155C1P1D1

EJ	NCBI Entrez, GenBank Report with Revision History, Accession No. D46420, Sasaki, T. <i>et al.</i> , National Center for Biotechnology Information (August 1995).	
EK	NCBI Entrez, GenBank Report with Revision History, Accession No. D54216, Fujiwara, T. <i>et al.</i> , National Center for Biotechnology Information (September 1995).	
EL	NCBI Entrez, GenBank Report with Revision History, Accession No. D68729, Kohara, Y. <i>et al.</i> , National Center for Biotechnology Information (December 1995).	
EM	NCBI Entrez, GenBank Report with Revision History, Accession No. D69248, Kohara, Y. <i>et al.</i> , National Center for Biotechnology Information (December 1995).	
EN	NCBI Entrez, GenBank Report with Revision History, Accession No. D65627, Kohara, Y. <i>et al.</i> , National Center for Biotechnology Information (December 1995).	
EO	NCBI Entrez, GenBank Report with Revision History, Accession No. D66221, Kohara, Y. <i>et al.</i> , National Center for Biotechnology Information (December 1995).	
EP	NCBI Entrez, GenBank Report with Revision History, Accession No. C02000, Okubo, K., National Center for Biotechnology Information (July 1996).	
EQ	NCBI Entrez, GenBank Report with Revision History, Accession No. W29377, Marra, M. <i>et al.</i> , National Center for Biotechnology Information (September 1996).	
ER	NCBI Entrez, GenBank Report with Revision History, Accession No. W32720, Hillier, L. <i>et al.</i> , National Center for Biotechnology Information (October 1996).	
ES	NCBI Entrez, GenBank Report with Revision History, Accession No. W60824, Hillier, L. <i>et al.</i> , National Center for Biotechnology Information (October 1996).	
ET	NCBI Entrez, GenBank Report with Revision History, Accession No. T70682, Shen, B. <i>et al.</i> , National Center for Biotechnology Information (October 1996).	
EU	NCBI Entrez, GenBank Report with Revision History, Accession No. AA094753, Liew, C.C., National Center for Biotechnology Information (October 1996).	
EV	NCBI Entrez, GenBank Report with Revision History, Accession No. AA133331, Hillier, L. <i>et al.</i> , National Center for Biotechnology Information (November 1996).	
EW	NCBI Entrez, GenBank Report with Revision History, Accession No. AA190058, Marra, M. <i>et al.</i> , National Center for Biotechnology Information (January 1997).	
EX	NCBI Entrez, GenBank Report with Revision History, Accession No. AA018953, Hillier, L. <i>et al.</i> , National Center for Biotechnology Information (January 1997).	
EY	NCBI Entrez, GenBank Report with Revision History, Accession No. AA240978, Marra, M. <i>et al.</i> , National Center for Biotechnology Information (March 1997).	
EZ	NCBI Entrez, GenBank Report with Revision History, Accession No. AA289560, Marra, M. <i>et al.</i> , National Center for Biotechnology Information (April 1997).	
FA	NCBI Entrez, GenBank Report with Revision History, Accession No. AA296993, Adams, M.D. <i>et al.</i> , National Center for Biotechnology Information (April 1997).	
FB	NCBI Entrez, GenBank Report with Revision History, Accession No. AA298937, Adams, M.D. <i>et al.</i> , National Center for Biotechnology Information (April 1997).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/733,311-Conf#8060
				Filing Date	December 12, 2003
				First Named Inventor	Ruben et al.
				Art Unit	1647
				Examiner Name	C. Saoud
Sheet	8	of	9	Attorney Docket Number	PF155C1P1D1

FC	NCBI Entrez, GenBank Report with Revision History, Accession No. AA312184, Adams, M.D. <i>et al.</i> , National Center for Biotechnology Information (April 1997).	
FD	NCBI Entrez, GenBank Report with Revision History, Accession No. AA312483, Adams, M.D. <i>et al.</i> , National Center for Biotechnology Information (April 1997).	
FE	NCBI Entrez, GenBank Report with Revision History, Accession No. AA356781, Adams, M.D. <i>et al.</i> , National Center for Biotechnology Information (April 1997).	
FF	NCBI Entrez, GenBank Report with Revision History, Accession No. AA412789, Marra, M. <i>et al.</i> , National Center for Biotechnology Information (May 1997).	
FG	NCBI Entrez, GenBank Report, Accession No. U67918, Jimenez, P.A. <i>et al.</i> , National Center for Biotechnology Information (July 1997).	
FH	NCBI Entrez, GenBank Report with Revision History, Accession No. AA472256, Marra, M. <i>et al.</i> , National Center for Biotechnology Information (June 1997).	
FI	NCBI Entrez, GenBank Report with Revision History, Accession No. C38464, Kohara, Y. <i>et al.</i> , National Center for Biotechnology Information (September 1997).	
FJ	NCBI Entrez, GenBank Report with Revision History, Accession No. C56505, Kohara, Y. <i>et al.</i> , National Center for Biotechnology Information (September 1997).	
FK	NCBI Entrez, GenBank Report with Revision History, Accession No. C57074, Kohara, Y. <i>et al.</i> , National Center for Biotechnology Information (September 1997).	
FL	NCBI Entrez, GenBank Report with Revision History, Accession No. C58558, Kohara, Y. <i>et al.</i> , National Center for Biotechnology Information (September 1997).	
FM	NCBI Entrez, GenBank Report with Revision History, Accession No. C58846, Kohara, Y. <i>et al.</i> , National Center for Biotechnology Information (September 1997).	
FN	NCBI Entrez, GenBank Report with Revision History, Accession No. C59317, Kohara, Y. <i>et al.</i> , National Center for Biotechnology Information (September 1997).	
FO	NCBI Entrez, GenBank Report with Revision History, Accession No. C59311, Kohara, Y. <i>et al.</i> , National Center for Biotechnology Information (September 1997).	
FP	NCBI Entrez, GenBank Report with Revision History, Accession No. AA605609, Clark, M. <i>et al.</i> , National Center for Biotechnology Information (September 1997).	
FQ	NCBI Entrez, GenBank Report with Revision History, Accession No. AA621871, NCI-CGAP, National Center for Biotechnology Information (October 1997).	
FR	NCBI Entrez, GenBank Report with Revision History, Accession No. AA621888, NCI-CGAP, National Center for Biotechnology Information (October 1997).	
FS	NCBI Entrez, GenBank Report with Revision History, Accession No. AA675470, Marra, M. <i>et al.</i> , National Center for Biotechnology Information (November 1997).	
FT	NCBI Entrez, GenBank Report with Revision History, Accession No. AA675519, Marra, M. <i>et al.</i> , National Center for Biotechnology Information (November 1997).	
FU	NCBI Entrez, GenBank Report with Revision History, Accession No. AA838994, Marra, M. <i>et al.</i> , National Center for Biotechnology Information (February 1998).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/733,311-Conf#8060
				Filing Date	December 12, 2003
				First Named Inventor	Ruben et al.
				Art Unit	1647
				Examiner Name	C. Saoud
				Attorney Docket Number	PF155C1P1D1
Sheet	9	of	9		

	FV	NCBI Entrez, GenBank Report with Revision History, Accession No. H35048, Lee, N.H. <i>et al.</i> , National Center for Biotechnology Information (April 1998).	
	FW	NCBI Entrez, GenBank Report with Revision History, Accession No. AA906051, NCI-CGAP, National Center for Biotechnology Information (May 1998).	
	FX	NCBI Entrez, GenBank Report with Revision History, Accession No. C78836, Ko, M.S.H. <i>et al.</i> , National Center for Biotechnology Information (June 1998).	
	FY	NCBI Entrez, GenBank Report with Revision History, Accession No. M79878, McCombie, W.R., National Center for Biotechnology Information (1992).	
	FZ	English language translation of WO 97/20929 (Document BQ).	
	GA	English language translation of JP 7-345689 (Document BH).	
	GB	English language translation of JP 8-103240 (Document BI).	
	GC	English language translation of JP 8-214378 (Document BN).	
	GD	English language translation of JP 10-330283 (Document BV).	
	GE	English language translation of JP 10-330284 (Document BW).	
	GF	English language translation of JP 10-330285 (Document BX).	
	GG	International Search Report for International Application No. PCT/US95/01790, mailed June 7, 1995.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--